GLPG 0187

Drug Profile

GLPG 0187

Alternative Names: GLPG-0187; IRAM

Latest Information Update: 27 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProStrakan
  • Developer Galapagos NV
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer metastases

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 09 Jun 2013 Galapagos NV completes a phase I trial in Cancer metastases in Netherlands (NCT01313598)
  • 01 Apr 2013 No development reported - Phase-I for Cancer metastases (in volunteers) in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top